NASDAQ:CGEN - Compugen Stock Price, Price Target & More

$4.00 -0.20 (-4.76 %)
(As of 04/22/2018 04:00 PM ET)
Previous Close$4.00
Today's Range$3.95 - $4.25
52-Week Range$2.25 - $5.40
Volume172,214 shs
Average Volume327,451 shs
Market Capitalization$205.17 million
P/E Ratio-5.56
Dividend YieldN/A
Beta0.26

About Compugen (NASDAQ:CGEN)

Compugen logoCompugen Ltd., a therapeutic discovery company, engages in the research, development, and commercialization of therapeutic and product candidates in Israel and Europe. The company's pipeline primarily includes early and preclinical stage immuno-oncology programs based on novel drug targets, such as immune checkpoint and myeloid protein target candidates to harness the immune system to provide treatment solutions in the areas of unmet medical needs in various cancer types and patient populations. Its antibody drug conjugate target candidates comprise CGEN-15001T, CGEN-15022, CGEN-15029, and CGEN-15137 for oncology; and therapeutic proteins include CGEN-15001, a fusion protein for autoimmune diseases, as well as CGEN myeloid target. The company was incorporated in 1993 and is headquartered in Holon, Israel.

Receive CGEN News and Ratings via Email

Sign-up to receive the latest news and ratings for CGEN and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:CGEN
CUSIPN/A
Phone972-3765-8585

Debt

Debt-to-Equity RatioN/A
Current Ratio5.04%
Quick Ratio5.04%

Price-To-Earnings

Trailing P/E Ratio-5.56
Forward P/E Ratio-5.33
P/E GrowthN/A

Sales & Book Value

Annual Sales$710,000.00
Price / Sales288.96
Cash FlowN/A
Price / CashN/A
Book Value$0.57 per share
Price / Book7.02

Profitability

EPS (Most Recent Fiscal Year)($0.72)
Net Income$-37,060,000.00
Net MarginsN/A
Return on Equity-87.08%
Return on Assets-72.10%

Miscellaneous

Employees98
Outstanding Shares51,290,000

How to Become a New Pot Stock Millionaire

Compugen (NASDAQ:CGEN) Frequently Asked Questions

What is Compugen's stock symbol?

Compugen trades on the NASDAQ under the ticker symbol "CGEN."

How were Compugen's earnings last quarter?

Compugen (NASDAQ:CGEN) announced its earnings results on Wednesday, February, 21st. The biotechnology company reported ($0.18) EPS for the quarter. View Compugen's Earnings History.

When is Compugen's next earnings date?

Compugen is scheduled to release their next quarterly earnings announcement on Tuesday, May, 8th 2018. View Earnings Estimates for Compugen.

What price target have analysts set for CGEN?

3 Wall Street analysts have issued 12-month price objectives for Compugen's shares. Their predictions range from $9.00 to $14.00. On average, they expect Compugen's share price to reach $11.50 in the next twelve months. View Analyst Ratings for Compugen.

Who are some of Compugen's key competitors?

Who are Compugen's key executives?

Compugen's management team includes the folowing people:
  • Dr. Anat Cohen-Dayag, Chief Exec. Officer, Pres and Director (Age 51)
  • Mr. Ari Krashin, Chief Financial and Operating Officer (Age 45)
  • Dr. Zurit Levine Ph.D., VP of Research & Discovery (Age 50)
  • Dr. John J. Hunter, VP of Antibody R&D (Age 55)
  • Mr. Martin S. Gerstel, Sr. Advisor (Age 77)

Has Compugen been receiving favorable news coverage?

Press coverage about CGEN stock has been trending somewhat positive recently, according to Accern. The research firm ranks the sentiment of press coverage by analyzing more than 20 million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Compugen earned a news sentiment score of 0.09 on Accern's scale. They also assigned news coverage about the biotechnology company an impact score of 44.71 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the stock's share price in the near future.

How do I buy shares of Compugen?

Shares of CGEN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Compugen's stock price today?

One share of CGEN stock can currently be purchased for approximately $4.00.

How big of a company is Compugen?

Compugen has a market capitalization of $205.17 million and generates $710,000.00 in revenue each year. The biotechnology company earns $-37,060,000.00 in net income (profit) each year or ($0.72) on an earnings per share basis. Compugen employs 98 workers across the globe.

How can I contact Compugen?

Compugen's mailing address is AZRIELI CENTER 26 HAROKMIM STREET BUILDING D, HOLON L3, 5885849. The biotechnology company can be reached via phone at 972-3765-8585 or via email at [email protected]


MarketBeat Community Rating for Compugen (CGEN)

Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  181 (Vote Outperform)
Underperform Votes:  147 (Vote Underperform)
Total Votes:  328
MarketBeat's community ratings are surveys of what our community members think about Compugen and other stocks. Vote "Outperform" if you believe CGEN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CGEN will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Compugen (NASDAQ:CGEN) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
3 Wall Street analysts have issued ratings and price targets for Compugen in the last 12 months. Their average twelve-month price target is $11.50, suggesting that the stock has a possible upside of 187.50%. The high price target for CGEN is $14.00 and the low price target for CGEN is $9.00. There are currently 3 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.003.003.003.00
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $11.50$14.00$14.00$14.00
Price Target Upside: 187.50% upside225.58% upside225.58% upside225.58% upside

Compugen (NASDAQ:CGEN) Consensus Price Target History

Price Target History for Compugen (NASDAQ:CGEN)

Compugen (NASDAQ:CGEN) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
3/29/2018CIBCInitiated CoverageOutperform -> OutperformLowView Rating Details
3/29/2018OppenheimerInitiated CoverageOutperform$9.00HighView Rating Details
5/19/2017FBR & CoSet Price TargetBuy$14.00HighView Rating Details
(Data available from 4/22/2016 forward)

Earnings

Compugen (NASDAQ:CGEN) Earnings History and Estimates Chart

Earnings by Quarter for Compugen (NASDAQ:CGEN)

Compugen (NASDAQ:CGEN) Earnings Estimates

2018 EPS Consensus Estimate: ($0.76)
2019 EPS Consensus Estimate: ($0.58)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20181($0.21)($0.21)($0.21)
Q2 20182($0.21)($0.18)($0.20)
Q3 20182($0.21)($0.18)($0.20)
Q4 20182($0.22)($0.10)($0.16)
Q1 20191($0.15)($0.15)($0.15)
Q2 20191($0.14)($0.14)($0.14)
Q3 20191($0.14)($0.14)($0.14)
Q4 20191($0.15)($0.15)($0.15)

Compugen (NASDAQ CGEN) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/8/2018        
2/21/2018n/a($0.18)ViewN/AView Earnings Details
11/7/2017Q3 2017($0.19)($0.19)ViewN/AView Earnings Details
8/2/20176/30/2017($0.17)($0.18)$0.21 millionViewListenView Earnings Details
5/9/20173/31/2017($0.18)($0.17)$0.06 millionViewListenView Earnings Details
2/15/2017Q416($0.18)($0.17)$0.13 million$0.05 millionViewListenView Earnings Details
11/7/2016Q316($0.14)($0.15)$0.41 million$0.07 millionViewN/AView Earnings Details
8/2/2016Q116($0.17)($0.13)$0.11 million$0.50 millionViewN/AView Earnings Details
5/10/2016Q1($0.16)($0.17)$0.12 million$0.09 millionViewListenView Earnings Details
2/9/2016Q415($0.11)($0.01)$3.33 million$8.30 millionViewN/AView Earnings Details
11/3/2015Q315($0.15)($0.13)$0.92 million$0.23 millionViewN/AView Earnings Details
8/4/2015Q215($0.14)($0.14)$1.58 million$0.22 millionViewN/AView Earnings Details
5/5/2015Q115($0.13)($0.12)$1.88 million$0.51 millionViewN/AView Earnings Details
2/10/2015Q414($0.08)($0.03)$3.70 million$6.60 millionViewN/AView Earnings Details
10/29/2014Q314($0.11)($0.11)$1.90 million$1.70 millionViewN/AView Earnings Details
8/6/2014Q214($0.10)($0.07)$1.85 million$2.00 millionViewN/AView Earnings Details
5/19/2014Q114($0.11)($0.04)$0.1620 million$2.10 millionViewN/AView Earnings Details
2/11/2014Q413($0.09)$0.1320 million$1.80 millionViewN/AView Earnings Details
10/29/2013Q313($0.12)$0.1080 million$1.60 millionViewN/AView Earnings Details
8/2/2013Q2 2013($0.09)$0.02 millionViewN/AView Earnings Details
4/25/2013Q1 2013($0.09)$0.16 millionViewN/AView Earnings Details
2/20/2013Q4 2012($0.15)ViewN/AView Earnings Details
11/5/2012Q312($0.10)ViewN/AView Earnings Details
8/7/2012Q2 2012($0.02)ViewN/AView Earnings Details
5/1/2012Q1 2012($0.12)ViewN/AView Earnings Details
2/7/2012Q4 2011($0.13)ViewN/AView Earnings Details
11/8/2011Q3 2011($0.10)ViewN/AView Earnings Details
8/2/2011Q2 2011($0.06)ViewN/AView Earnings Details
5/11/2011Q1 2011($0.06)ViewN/AView Earnings Details
2/15/2011Q4 2010($0.06)ViewN/AView Earnings Details
10/26/2010Q3 2010($0.05)ViewN/AView Earnings Details
7/27/2010Q2 2010($0.06)($0.03)ViewN/AView Earnings Details
4/27/2010Q1 2010($0.05)($0.08)ViewN/AView Earnings Details
2/9/2010Q4 2009($0.08)($0.07)ViewN/AView Earnings Details
10/27/2009Q3 2009($0.07)($0.06)ViewN/AView Earnings Details
7/28/2009Q2 2009$0.08ViewN/AView Earnings Details
5/12/2009Q1 2009($0.08)ViewN/AView Earnings Details
2/11/2009Q4 2008($0.13)ViewN/AView Earnings Details
11/13/2008Q3 2008($0.12)ViewN/AView Earnings Details
7/29/2008Q2 2008($0.10)ViewN/AView Earnings Details
5/14/2008Q1 2008($0.09)ViewN/AView Earnings Details
2/19/2008Q4 2007($0.11)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Compugen (NASDAQ:CGEN) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Compugen (NASDAQ CGEN) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 9.50%
Institutional Ownership Percentage: 21.17%
Insider Trading History for Compugen (NASDAQ:CGEN)
Institutional Ownership by Quarter for Compugen (NASDAQ:CGEN)

Compugen (NASDAQ CGEN) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
(Data available from 1/1/2013 forward)

Headlines

Compugen (NASDAQ CGEN) News Headlines

Source:
DateHeadline
Compugen (CGEN) Expected to Post Earnings of -$0.20 Per ShareCompugen (CGEN) Expected to Post Earnings of -$0.20 Per Share
www.americanbankingnews.com - April 22 at 7:34 AM
Blog Exposure - Preclinical Data Presented by Bayer at AACR Highlights Compugen’s BAY 1905254 Efficacy in Cancer ImmunotherapyBlog Exposure - Preclinical Data Presented by Bayer at AACR Highlights Compugen’s BAY 1905254 Efficacy in Cancer Immunotherapy
finance.yahoo.com - April 19 at 8:32 AM
Bayers ILDR2 inhibitor shows encouraging action in preclinical studies, discoverer Compugen up 4%Bayer's ILDR2 inhibitor shows encouraging action in preclinical studies, discoverer Compugen up 4%
seekingalpha.com - April 17 at 10:12 AM
BRIEF-Compugen Ltd - Bayer Plans To Advance Cancer Immunotherapy Program Into First-In-Human Trials In 2018BRIEF-Compugen Ltd - Bayer Plans To Advance Cancer Immunotherapy Program Into First-In-Human Trials In 2018
www.reuters.com - April 17 at 8:53 AM
Compugen (CGEN) Reports Preclinical Data by Bayer AG Highlighting Efficacy of BAY 1905254 (formerly the CGEN ...Compugen (CGEN) Reports Preclinical Data by Bayer AG Highlighting Efficacy of BAY 1905254 (formerly the CGEN ...
www.streetinsider.com - April 17 at 8:53 AM
Preclinical Data Presented by Bayer at AACR Highlights BAY 1905254, Formerly the CGEN-15001T Program, Efficacy in Cancer ImmunotherapyPreclinical Data Presented by Bayer at AACR Highlights BAY 1905254, Formerly the CGEN-15001T Program, Efficacy in Cancer Immunotherapy
finance.yahoo.com - April 17 at 8:53 AM
Compugens (CGEN) CEO Anat Cohen-Dayag on MedImmune License Agreement Call (Transcript)Compugen's (CGEN) CEO Anat Cohen-Dayag on MedImmune License Agreement Call (Transcript)
seekingalpha.com - April 5 at 5:06 PM
Zacks: Analysts Anticipate Compugen (CGEN) Will Announce Earnings of -$0.20 Per ShareZacks: Analysts Anticipate Compugen (CGEN) Will Announce Earnings of -$0.20 Per Share
www.americanbankingnews.com - April 5 at 9:42 AM
Oppenheimer Research Analysts Decrease Earnings Estimates for Compugen (CGEN)Oppenheimer Research Analysts Decrease Earnings Estimates for Compugen (CGEN)
www.americanbankingnews.com - April 5 at 8:52 AM
[$$] AstraZeneca receives regulatory boost for oncology drugs[$$] AstraZeneca receives regulatory boost for oncology drugs
finance.yahoo.com - April 3 at 5:18 PM
Compugen Takes Lumps After AstraZeneca PactCompugen Takes Lumps After AstraZeneca Pact
www.baystreet.ca - April 2 at 5:13 PM
Compugen Announces Exclusive License Agreement With MedImmune for the Development of Bi-Specific and Multi ...Compugen Announces Exclusive License Agreement With MedImmune for the Development of Bi-Specific and Multi ...
www.prnewswire.com - April 2 at 5:13 PM
Compugen (CGEN) Announces Pact With MedImmune for Development of Bi-Specific and Multi-Specific Antibody ...Compugen (CGEN) Announces Pact With MedImmune for Development of Bi-Specific and Multi-Specific Antibody ...
www.streetinsider.com - April 2 at 9:00 AM
Compugen Announces Exclusive License Agreement With MedImmune for the Development of Bi-Specific and Multi-Specific Antibody ProductsCompugen Announces Exclusive License Agreement With MedImmune for the Development of Bi-Specific and Multi-Specific Antibody Products
finance.yahoo.com - April 2 at 9:00 AM
Compugen (CGEN) Lowered to "Strong Sell" at ValuEngineCompugen (CGEN) Lowered to "Strong Sell" at ValuEngine
www.americanbankingnews.com - March 31 at 3:20 PM
Oppenheimer Comments on Compugen Ltd.s Q1 2019 Earnings (CGEN)Oppenheimer Comments on Compugen Ltd.'s Q1 2019 Earnings (CGEN)
www.americanbankingnews.com - March 30 at 7:24 AM
Compugen (CGEN) Earns Outperform Rating from Analysts at CIBCCompugen (CGEN) Earns Outperform Rating from Analysts at CIBC
www.americanbankingnews.com - March 29 at 10:49 PM
Benzingas Top Upgrades, Downgrades For March 29, 2018Benzinga's Top Upgrades, Downgrades For March 29, 2018
www.benzinga.com - March 29 at 5:16 PM
UPDATE: Oppenheimer Starts Compugen (CGEN) at OutperformUPDATE: Oppenheimer Starts Compugen (CGEN) at Outperform
www.streetinsider.com - March 29 at 8:45 AM
Compugen (CGEN) Now Covered by OppenheimerCompugen (CGEN) Now Covered by Oppenheimer
www.americanbankingnews.com - March 29 at 8:36 AM
Compugen: Near-Term Catalysts Will Force Significant RevaluationCompugen: Near-Term Catalysts Will Force Significant Revaluation
seekingalpha.com - March 28 at 5:07 PM
At $3.95, Is Compugen Ltd (NASDAQ:CGEN) A Buy?At $3.95, Is Compugen Ltd (NASDAQ:CGEN) A Buy?
finance.yahoo.com - March 28 at 5:07 PM
Compugen Announces Appointment of Henry Adewoye, MD, as Chief Medical OfficerCompugen Announces Appointment of Henry Adewoye, MD, as Chief Medical Officer
finance.yahoo.com - March 26 at 8:38 AM
Compugen Ltd (NASDAQ:CGEN): Should The Future Outlook Worry You?Compugen Ltd (NASDAQ:CGEN): Should The Future Outlook Worry You?
finance.yahoo.com - March 20 at 5:05 PM
Compugen (CGEN) Downgraded by ValuEngineCompugen (CGEN) Downgraded by ValuEngine
www.americanbankingnews.com - March 20 at 12:54 AM
-$0.21 Earnings Per Share Expected for Compugen Ltd. (CGEN) This Quarter-$0.21 Earnings Per Share Expected for Compugen Ltd. (CGEN) This Quarter
www.americanbankingnews.com - March 19 at 7:56 AM
Analyzing Compugen (CGEN) and Ionis Pharmaceuticals (IONS)Analyzing Compugen (CGEN) and Ionis Pharmaceuticals (IONS)
www.americanbankingnews.com - March 11 at 6:02 AM
Compugen to Present at the Cowen and Company 38th Annual Health Care ConferenceCompugen to Present at the Cowen and Company 38th Annual Health Care Conference
finance.yahoo.com - March 8 at 8:42 AM
Compugen (CGEN) Raised to "Hold" at ValuEngineCompugen (CGEN) Raised to "Hold" at ValuEngine
www.americanbankingnews.com - March 4 at 10:00 PM
ARK Investment Management LLC Purchases 1,103,384 Shares of Compugen Ltd. (CGEN)ARK Investment Management LLC Purchases 1,103,384 Shares of Compugen Ltd. (CGEN)
www.americanbankingnews.com - February 27 at 4:24 AM
Compugen (CGEN) Downgraded by Zacks Investment Research to "Sell"Compugen (CGEN) Downgraded by Zacks Investment Research to "Sell"
www.americanbankingnews.com - February 26 at 7:40 PM
FY2018 EPS Estimates for Compugen Ltd. (CGEN) Cut by Jefferies GroupFY2018 EPS Estimates for Compugen Ltd. (CGEN) Cut by Jefferies Group
www.americanbankingnews.com - February 26 at 7:58 AM
Financial Analysis: Compugen (CGEN) vs. Senomyx (SNMX)Financial Analysis: Compugen (CGEN) vs. Senomyx (SNMX)
www.americanbankingnews.com - February 24 at 9:26 AM
Compugen Ltd. Expected to Post Q1 2018 Earnings of ($0.21) Per Share (CGEN)Compugen Ltd. Expected to Post Q1 2018 Earnings of ($0.21) Per Share (CGEN)
www.americanbankingnews.com - February 23 at 10:02 AM
Form 6-K COMPUGEN LTD For: Feb 21 - StreetInsider.com - StreetInsider.comForm 6-K COMPUGEN LTD For: Feb 21 - StreetInsider.com - StreetInsider.com
www.streetinsider.com - February 23 at 8:39 AM
Compugen Ltd.: An Undervalued Disruptive Innovation Company - Seeking AlphaCompugen Ltd.: An Undervalued Disruptive Innovation Company - Seeking Alpha
seekingalpha.com - February 22 at 8:35 AM
Compugen (CGEN) Releases  Earnings ResultsCompugen (CGEN) Releases Earnings Results
www.americanbankingnews.com - February 21 at 12:10 PM
Form 6-K COMPUGEN LTD For: Feb 21Form 6-K COMPUGEN LTD For: Feb 21
www.streetinsider.com - February 21 at 8:37 AM
Compugen Reports Fourth Quarter and Full Year 2017 ResultsCompugen Reports Fourth Quarter and Full Year 2017 Results
www.prnewswire.com - February 21 at 7:27 AM
Compugen (CGEN) to Release Quarterly Earnings on WednesdayCompugen (CGEN) to Release Quarterly Earnings on Wednesday
www.americanbankingnews.com - February 14 at 4:50 AM
Wired News – Compugen Reports Publication of Discovery and Validation of ILDR2 as A Novel Immune Checkpoint and Its Use for Auto-Immune DiseasesWired News – Compugen Reports Publication of Discovery and Validation of ILDR2 as A Novel Immune Checkpoint and Its Use for Auto-Immune Diseases
finance.yahoo.com - February 8 at 8:21 AM
Compugen Fourth Quarter and Full Year 2017 Conference Call Scheduled for Wednesday, February 21, 2018 at 10:00 AM ETCompugen Fourth Quarter and Full Year 2017 Conference Call Scheduled for Wednesday, February 21, 2018 at 10:00 AM ET
finance.yahoo.com - February 8 at 8:21 AM
Compugen Announces Publication of the Discovery of ILDR2 as a Novel Immune Checkpoint and Its Use for the Treatment of Autoimmune Diseases in Two Back-to-Back Papers in The Journal of ImmunologyCompugen Announces Publication of the Discovery of ILDR2 as a Novel Immune Checkpoint and Its Use for the Treatment of Autoimmune Diseases in Two Back-to-Back Papers in The Journal of Immunology
finance.yahoo.com - February 6 at 9:41 AM
Compugen (CGEN) & Yield10 Bioscience (YTEN) Critical ComparisonCompugen (CGEN) & Yield10 Bioscience (YTEN) Critical Comparison
www.americanbankingnews.com - February 3 at 2:44 PM
Compugen (CGEN) Downgraded by Zacks Investment ResearchCompugen (CGEN) Downgraded by Zacks Investment Research
www.americanbankingnews.com - January 22 at 7:52 PM
Zacks Investment Research Upgrades Compugen (CGEN) to "Buy"Zacks Investment Research Upgrades Compugen (CGEN) to "Buy"
www.americanbankingnews.com - January 19 at 8:44 PM
Compugen Presents New Preclinical Data Demonstrating the Distinctive Features of the PVRIG Pathway in Immuno-Oncology and the Potential of COM701 for Treating Multiple Solid TumorsCompugen Presents New Preclinical Data Demonstrating the Distinctive Features of the PVRIG Pathway in Immuno-Oncology and the Potential of COM701 for Treating Multiple Solid Tumors
finance.yahoo.com - January 18 at 11:00 AM
Compugen (CGEN) Lifted to "Hold" at Zacks Investment ResearchCompugen (CGEN) Lifted to "Hold" at Zacks Investment Research
www.americanbankingnews.com - January 9 at 7:12 PM
Contrasting NewLink Genetics (NLNK) & Compugen (CGEN)Contrasting NewLink Genetics (NLNK) & Compugen (CGEN)
www.americanbankingnews.com - January 7 at 1:10 AM
Compugen Announces Presentations at Three Upcoming Cancer ... - PR Newswire (press release)Compugen Announces Presentations at Three Upcoming Cancer ... - PR Newswire (press release)
www.prnewswire.com - January 2 at 9:57 AM

SEC Filings

Compugen (NASDAQ:CGEN) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Compugen (NASDAQ:CGEN) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Compugen (NASDAQ CGEN) Stock Chart for Sunday, April, 22, 2018

Loading chart…

This page was last updated on 4/22/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.